Emerging studies suggest an association between ADHD and maternal polycystic ovary syndrome, prompting a closer look at shared biological factors and developmental risks in women and children.
Attention-deficit/hyperactivity disorder remains one of the most common neurodevelopmental conditions in the United States, affecting attention, impulse control, activity level and emotional regulation. The Centers for Disease Control and Prevention says 11.4% of children aged 3 to 17 have at some point been diagnosed with ADHD, while the National Institute of Mental Health puts current adult prevalence at 4.4%. Both agencies note that diagnosis rates are higher in boys and men than in girls and women, a gap that has helped fuel concern that ADHD has long been underrecognised in females.
That concern is part of why researchers have been paying closer attention to the possible links between ADHD and polycystic ovary syndrome, now increasingly referred to by some clinicians and advocates as polyendocrine metabolic ovarian syndrome, or PMOS. According to the PCOS Nutrition Center, the condition and ADHD may overlap in ways that are easy to miss, particularly because women with ADHD often present with inattentiveness, disorganisation, poor time management and emotional dysregulation rather than obvious hyperactivity. Those symptoms can also resemble fatigue, sleep disturbance, anxiety and difficulty concentrating, all of which may appear in PMOS.
The research so far suggests an association, not a cause-and-effect relationship. A systematic review and meta-analysis published in the National Library of Medicine examined 19 studies covering more than 1.6 million mothers and more than 2.2 million children and found that maternal PCOS was linked with higher odds of neurodevelopmental outcomes, including ADHD and autism spectrum disorder, in offspring. Earlier register-based research also found a higher risk of ADHD diagnosis among children born to mothers with PCOS, with some findings pointing to a stronger signal among girls.
Scientists have proposed several possible explanations. One theory focuses on prenatal androgen exposure, since androgens such as testosterone can cross the placenta and may influence fetal brain development during critical stages. But the evidence is far from settled. The meta-analysis found the association regardless of the child’s sex, and individual studies have not consistently linked maternal testosterone levels directly with ADHD-related behaviour in children. That has pushed researchers to look more broadly at shared genetics, maternal metabolic health, inflammation, environmental exposures and other pregnancy-related factors.
The broader picture is also complicated by the fact that ADHD itself has a strong genetic component and can be shaped by early-life influences such as premature birth, low birthweight and prenatal exposures. The CDC says treatment typically involves medication, behaviour therapy and other interventions, while nutrition, exercise and sleep can support overall health but are not substitutes for evidence-based care. The emerging PMOS-ADHD literature does not suggest that the condition causes ADHD, only that it may be part of a wider cluster of biological and developmental risks. For women who suspect attention problems may be going unrecognised, experts say a formal evaluation can be worthwhile, especially when symptoms persist across settings and interfere with daily life.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
